Alane P. Barnes - 11 May 2021 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Chief Legal Officer
Signature
/s/ Alane P. Barnes
Issuer symbol
BCRX
Transactions as of
11 May 2021
Net transactions value
-$642,449
Form type
4
Filing time
13 May 2021, 16:43:13 UTC
Next filing
13 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $7,795 +1,648 +1.5% $4.73 111,923 11 May 2021 Direct
transaction BCRX Common Stock Options Exercise $47,047 +33,132 +30% $1.42* 145,055 11 May 2021 Direct
transaction BCRX Common Stock Options Exercise $370,600 +68,000 +47% $5.45 213,055 11 May 2021 Direct
transaction BCRX Common Stock Sale $1,237,471 -102,780 -48% $12.04 110,275 11 May 2021 Direct F1
transaction BCRX Common Stock Options Exercise $169,580 +35,852 +33% $4.73 146,127 12 May 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -1,648 -4.4% $0.000000 35,852 11 May 2021 Common Stock 1,648 $4.73 Direct
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -33,132 -100% $0.000000* 0 11 May 2021 Common Stock 33,132 $1.42 Direct
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -68,000 -100% $0.000000* 0 11 May 2021 Common Stock 68,000 $5.45 Direct F3
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -35,852 -100% $0.000000* 0 12 May 2021 Common Stock 35,852 $4.73 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.00 to $12.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F2 The reporting person engaged in a non-market exercise and hold transaction with respect to these stock options and the underlying shares.
F3 The option vested upon the achievement of performance-based vesting criteria with respect to 17,000 shares on each of May 26, 2014, December 19, 2014, May 13, 2015 and December 3, 2020.